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is costly and sometimes infeasible in many middle-income countries (MICs). We 
explored the combination of data-mining and a large claims database to estimate 
the direct medical costs of HER2-positive breast cancer (BC) treatment in Iran and 
the fraction of total costs from trastuzumab use. Methods: Data from 21/03/2011-
20/03/2014 were examined using data-mining to determine clinical stages. R-based 
classification algorithms were designed based on medication patterns including 
drug combinations and/or sequences of drugs in respect of three index dates (early, 
loco-regional and advanced BC). These algorithms were then validated using patient 
dossiers from the Cancer Institute of Iran and used to analyze claims data from 
the Iran Social Security Organization, a health insurer which covers approximately 
50% of all Iranians (~40 million). A healthcare perspective was used to calculate 
the absolute and relative costs of medical services. Results: With an 84% (43/51) 
accuracy rate, 1,295 patients were identified and divided into three BC stages (early 
(n= 802), loco-regional (n= 125), advanced (n= 218); some patients were categorized 
into > 1 stage (n= 177), none (n= 284) due to insufficient information, while some 
were excluded (n= 54) due to incomplete follow-up). Mean age per stage was 45, 46 
and 48 years, respectively, while mean follow-up in all stages was approximately 
one year. Average costs of direct medical care in early, loco-regional and advanced 
stages were € 11,796 (95%CI:€ 9,356-€ 12,498), € 8,253 (95%CI:€ 6,843-€ 10,002) and € 17,742 
(95%CI:€ 15,720-€ 19,505), respectively. ConClusions: When comprehensive patient 
registries are infeasible or costly, validated data-mining algorithms can support real-
world cost-effectiveness analyses in MICs and thereby help to optimize reimbursement 
decisions. The accuracy of data-mining would be improved, if electronic reports of 
diagnostic tests were generated and included in the classification algorithms as well.
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objeCtives: The Cancer Drugs Fund (CDF) was created in 2010 to pay for oncology 
indications that were not approved by the National Institute for Health and Care 
Excellence (NICE) and were not routinely available within the NHS in England. After 
a consultation process, it was agreed that from July 2016, NICE will appraise all new 
licenced cancer indications and decide whether they are eligible for inclusion in 
the CDF, which will become a ‘managed access fund’ This research estimates the 
number of current CDF indications that may be eligible for the new CDF following 
its reform. Methods: As of November 2015, there were 48 medicines/indications 
on the CDF. Information on these products was combined with data from historical 
NICE technology appraisals (TAs), published October 2007-December 2015, and from 
other sources. We used a simple set of rules to predict the funding category to which 
each indication would be assigned: (1) funded for routine commissioning; (2) funded 
on the new CDF for a limited period; and (3) not funded. Results: Of the 48 current 
CDF medicines/indications, 3 (6%) were likely to receive positive NICE appraisal and 
therefore enter routine commissioning, and 67% (n= 32/48) were judged to fall into 
the ‘not funded’ category. The remaining 13 may have the potential to be funded 
temporarily through the new CDF. ConClusions: This research suggests that the 
recent reform to the CDF may lead to a substantial decline in the number of cancer 
medicines available to patients in England. However, it remains to be seen exactly 
how NICE Appraisal Committees will interpret the new guidance, and the nature 
of the managed access contracts and data collection processes that will be forged 
between manufacturers and NHS England.
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2012 To 2014, USINg THE fRENCH HEALTH INSURANCE DATABASE (SNIIRAM)
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objeCtives: The aim of this study is to assess and analyze health care expenditure 
trends by disease between 2012 and 2014, based on a top-down allocation of expend-
iture using the French health insurance database. Methods: Using information 
about 56 millions of individuals from the general scheme insurance database (86% 
of the French population), we identified all people who received care for each of 57 
groups of diseases or medical events or treatments, which are frequent, severe and/
or costly. Algorithms have been applied to each patient, using ICD-10 diagnoses for 
long-term chronic diseases or hospital stays, specific drugs or medical procedures. 
Annual costs of all reimbursed expenditures (outpatient/inpatient care, disability/
sickness benefits) were extracted per individual. A top-down method was used to 
allocate expenditure to each of the 57 diseases based on the average expenditure 
by disease calculated for individuals with only one disease. This was done for 2012, 
2013 and 2014 in order to analyze trends. Results: In 2014, among the 155 billion 
euros of expenditures (all insurance schemes), 33.9 billion were related to isolated 
hospitalizations with an average annual growth rate of 2%, 22.6 billion to psychiatric 
disorders and treatments (+1.8%/year), 16.1 to cancer (+3.6%/year), 16.2 to cardio-
vascular diseases (+.3.1%/year), 7.9 to diabetes (+2.6%/year), 6.9 to neurologic disor-
ders (+3.6%%/year). The highest increase was observed for Liver/pancreas diseases, 
essentially due to hepatitis C drugs: +864 million € compared to 2012, giving a total 
of 2.3 billion € in 2014. A more detailed analysis of expenditures by diseases and of 
main cost drivers will also be presented. ConClusions: Our study provides help-
ful information to policy makers by monitoring the performance of the health care 
system at a disease-based level. This tool can also be used to forecast the impact of 
ageing and epidemiologic patterns on health expenditures.
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index stay and main comorbidities. A cox and a Poisson models were used to esti-
mate the increase risk of death while adjusting on the PS. Sensitivity analyses were 
performed to explore the robustness of the results. Results: Data from 482 ICD and 
964 PS matched controls were extracted. The 2 groups were very similar when com-
pared with the variables used to calculate the PS. Significant increase of death rates 
was found in CDI patients with HRs of 1.65 (CI95%= [1.33;2.04]) unadjusted and 1.58 
(CI95%= [1.27;1.97]) adjusted on PS. The PS adjusted RRs were 1.78 (CI95%= [1.18;2.70]) 
at 28 days, 1.52 (CI95%= [1.17;1.98]) at 3 months, 1.52 (CI95%= [1.20;1.93]) at 6 months 
and 1.64 (CI95%= [1.32;2.03]) at 12 months. Sensitivity analyses were performed and 
lead to similar result : patients for whom the CDI infection was coded as the main 
diagnosis (HR= 1.90 (CI95%= [1.27;2.86]) ; Matched controls hospitalized for a disease 
with diarrhea (HR= 1.44 (CI95%= [1.15;1.79])) ; Patients not rehospitalized for CDI after 
the index stay (HR= 1.73 (CI95%= [1.37;2.18])). ConClusions: CDI infection leads to 
a significant one year increase of death rate when compared to similar patients in 
terms of age, gender, comorbidities and length of stay.
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objeCtives: Association between change in BMI over a 1-year period and the 
incidence of hypertension was examined based on real-world data in Japan. This 
was a sub-study of the main study which was reported previously (ISPOR Europe, 
2015). Methods: This was a retrospective study using a database composed of 
annual health checkup and claims data (MinaCare Co., Ltd.). A subset of subjects 
of the main study was selected for this study, which was those with at least 1 year 
of record prior to 2011, non-missing blood pressure (BP) and body mass index (BMI) 
values in both years (2011/Baseline, 2012), and aged≥ 20 years at the 2011 checkup. 
Diagnosis of hypertension was based on either SBP≥ 140mmHg/DBP≥ 90mmHg or 
prescription of antihypertensive medications based on physician diagnosis (ICD-10 
codes I10-I15) within 1 year prior to checkup. Results: A total of 251,043 subjects 
[Female 27.0%; Age 44.0/11.4 (mean/SD); diagnosis of hypertension (HTN) at baseline 
18.7%] were analyzed. At baseline, the mean BMI across the age categories ranged 
between 20.7~22.3 for females and 22.7~24.1 for males. Mean percent change in BMI 
from 2011 to 2012 decreased with increasing age category for both sexes. Among 
those without HTN at baseline, the odds of HTN in 2012 increased with increasing 
BMI change categories for both sexes, after controlling for age, baseline BMI, base-
line BP, and 2-way interactions. The association was stronger for males compared 
to females with the odds-ratio (95%CI) of 0.662 (0.607~0.721), 0.774 (0.719~0.832), 
1.284 (1.211~1.362), 1.764 (1.651~1.885) for %BMI change category of ≤ -1%, -1%~-0.5%, 
0.5%~1%, ≥ 1%, respectively, where no change (-0.5%~+0.5%) was the refer-
ence. ConClusions: Incidence of HTN was positively associated with increasing 
level of change in BMI over the 1-year period, even after controlling for baseline BMI, 
BP and other factors. This suggests that controlling weight has impact on HTN even 
over a short period.
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objeCtives: To determine the sensitivity and specificity of software based on natu-
ral language processing to classify PubMed abstracts relevant to the humanistic 
or economic burden of disease. Methods: We developed an online database of 
abstracts of over 100,000 studies identified by a systematic search of PubMed on 
the humanistic and economic burden of disease (www.heoro.com). We manually 
indexed 10,000 abstracts to one or more study types: PRO study (with subtypes 
PRO validation study and Utility study), Costs and Resource use studies (Direct and 
indirect costs, resource use, treatment patterns and adherence), Economic models 
(cost-effectiveness, cost-utility, cost-benefit and other models) and mortality, as well 
as geographical location. We used this training set and expert assessment to itera-
tively develop classifiers from text, MeSH headings and metadata in the abstracts. 
We then assessed the accuracy of the classifiers on samples of the remaining 90,000 
abstracts by expert checking of 200 abstracts scoring positive and 400 negative for 
each study subtype. Results: The classifiers had a sensitivity and specificity of 96% 
for PRO study identification, sensitivity of 87 to 99% and specificity of 93 to 100% for 
economic model types, sensitivity of 79 to 99% and specificity of 92 to 98% for costs 
and resource use study subtypes, and sensitivity of 82% and specificity of 97% for 
mortality studies. They also identified randomised controlled trials and systematic 
reviews with 93-95% sensitivity and 99% specificity. Indexing to geographical loca-
tion was 97% accurate in an analysis of 200 abstracts. ConClusions: With overall 
accuracy of around 95%, the classifiers compare well with human indexing of study 
types. As 90,000 abstracts could be indexed accurately within hours, this method 
facilitates a highly streamlined approach to identifying relevant data for health 
economics and outcomes research.
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objeCtives: Patient registries play an important role in obtaining real-world 
evidence of the cost-effectiveness of treatments. However, their implementation 
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orthopedics (2) and other indications (5). 79% (23/29) were positive recommenda-
tions; 96% (22/23) of which included cost-saving claims, with the sole exception being 
based on comparable resource utilization. Nevertheless, for the 6 not recommended 
appraisals, the level of clinical evidence was cited as key. ConClusions: To date, 
relatively few devices have been appraised under MTEP. Outcomes have been mostly 
positive but, unlike Technology Appraisal Guidance, MTEP guidance is non-binding. 
Importantly, being cost-saving is a criteria for consideration under MTEP, precluding 
inclusion of high-cost innovative technologies for which timely access may be par-
ticularly challenging. France has a national assessment body (CNEDiMTS) targeted to 
the appraisal of new/innovative medical technologies, which may form a better model 
for involvement of national appraisal bodies in device reimbursement.
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DECISIoN-ANALyTIC BENEfIT-HARM ANALySIS
Sroczynski G1, Esteban E1, Widschwendter A2, Oberaigner W3, Borena W2, von Laer D2, 
Hackl M4, Endel G5, Siebert U6
1UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - 
Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 2Medical University 
Innsbruck, Innsbruck, Austria, 3Tirol Kliniken Innsbruck, Innsbruck, Austria, 4Statistics Austria, 
Austrian National Cancer Registry, Directorate Social Statistics, Statistics Austria, Vienna, Austria, 
5Main Association of Austrian Social Insurance Institutions, Vienna, Austria, 6Harvard Medical 
School, Institute for Technology Assessment & Department of Radiology, Hall i.T., Austria
objeCtives: To systematically evaluate the benefit-harm trade-off of different 
cervical cancer primary screening strategies for the Austrian context. Methods: 
A Markov-state-transition model was applied to evaluate different screening strate-
gies that differ by primary test (cytology, p16/Ki-67-testing, and HPV-testing alone or 
in combinations), screening interval, age, and follow-up algorithms for test-positive 
women. We used Austrian clinical and epidemiological data, along with test accu-
racy data from international meta-analyses and trials. Predicted outcomes were 
reduction in cervical cancer incidence/-mortality, overtreatment (defined as coniza-
tion with histological diagnosis of no lesion or a lesion grade CIN1), and incremental 
harm-benefit ratios (IHBR) measured in numbers of additional overtreatments per 
prevented cervical cancer death. Comprehensive sensitivity analyses were per-
formed. Results: Based on our results, HPV primary screening strategies are more 
effective compared with cytology or p16/Ki-67-testing alone. Adopting risk-based 
follow-up algorithms including p16/Ki-67-triage for women with ASCUS/LSIL and 
colposcopy referral for women with HSIL/p16/Ki-67-positivity can reduce overtreat-
ment. In the base-case analysis (31-43% screening adherence in women below 60 
years of age), biennial HPV-based screening achieved an acceptable benefit-harm 
balance (IHBR: 45 overtreatments per prevented cancer death). Annual screening 
strategies resulted in much higher IHBRs of 131-355 overtreatments per prevented 
cancer death. However, the optimal choice of screening depends on a woman’s 
individual benefit-harm trade-off threshold. Based on the IHBRs, the screening 
interval may be extended to three years in populations with screening adherence 
of 40%-60% and to 5 years with higher adherence rates. Varying the age at screen-
ing initiation from 18 to 24 years reduced overtreatment without significant loss 
in effectiveness. ConClusions: Based on our analysis, HPV-based screening in 
women 30 years or older and cytology in younger women at screening intervals 
of at least 2 years incorporating a risk-based follow-up algorithm can be recom-
mended for the Austrian screening setting. Screening should be initiated in women 
of the age 20-24 years.
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ADoPTIoN of TRANSCATHETER MITRAL vALvE REPAIR IN gERMANy: 
UTILIzATIoN PATTERNS AND CASE voLUMES CoMPARED To MITRAL vALvE 
SURgERy IN THE PERIoD 2010-2014
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objeCtives: The German healthcare system was among the first markets to intro-
duce transcatheter mitral valve repair (TMVR) in routine care for patients suffering 
from mitral valve insufficiency. Our objective was to estimate the impact of TMVR 
availability on overall mitral valve repair volumes and competing therapies in this 
real-world setting. Methods: Therapy- and age-specific procedure volumes were 
collected from German Federal Statistics Office databases for TMVR and mitral 
valve surgery for the period 2010 through 2014. We computed therapy-specific and 
total procedure volumes and growth stratified by age groups < 65, 65-74, 75-84, and 
> 85 years, and in total. Results: In the time period 2010 to 2014 overall procedure 
volumes grew from 17,521 to 24,033 (+37%). This growth was driven by both TMVR 
(508 to 3,715; +631%) and surgical procedure growth (17,013 to 20,318; +19%). The 
share of TMVR as percent of total procedures grew from 2.9% to 15.5% over the 
5-year period. In 2014, TMVR use reached 4%, 13%, 26%, and 68% in the studied age 
groups. Absolute TMVR procedure growth was highest in age group 75-84 years 
(+1,606). Concurrently, surgical volumes grew in all age groups, except for age > 85 
years, with the highest absolute growth in younger patients (+2,079 in age group 
< 65 years). ConClusions: The availability of TMVR has contributed to pronounced 
growth in mitral valve repair in Germany, specifically in elderly populations previ-
ously left untreated. At the same time, surgical procedure volumes continued to 
grow substantially in the study period in all age segments, except for the group of 
very elderly patients.
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objeCtives: It is widely accepted that medical innovation includes many 
costly activities, and that it is a key driver of rising health care expenditures. 
Understanding the relationship between medical innovation and health care 
expenditures is critical for health policy makers to effectively make resource allo-
cation decisions. This study seeks to investigate the relationship between medical 
innovation and health care expenditures. Methods: We assessed data from the 
World Intellectual Property Organization and World Bank statistics for the year 2014, 
which included data from 72 countries. The number of patent publications in the 
categories of medical technology, biotechnology, and pharmaceuticals were included 
as medical innovation indicators; public heath, health care costs per capita, and 
total health care costs (percentage of gross domestic product [GDP]) were included 
as indicators of health care-related expenditures. A canonic correlation analysis 
(CCA) was performed to examine the degree of association between the sets of 
medical innovation and health care expenditure variables. Results: Study results 
indicate that there is a strong positive correlation between medical innovation and 
health care expenditure variables (rc= 0.68, p< 0.001). ConClusions: In light of 
this study, health policy makers should manage the relationship between medical 
innovation and health care expenditures with a focus on accessibility. Improved 
communication channels in the social system, increased international coopera-
tion, and the determination of a proper balance between the benefits and costs of 
innovation may help to continue improving medical innovation and enhance health 
care accessibility. We hope that the study results offer an increased awareness of 
the relationship and balance between innovation and expenditure, and will help 
to create an improved health system.
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CoMPARISoN of TIME To REIMBURSEMENT DECISIoN of INNovATIvE 
PHARMACEUTICALS IN EURoPE
Hernandez J, Nientker K, Hensen M
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objeCtives: Knowledge is limited concerning the differences in time-to-decision 
between marketing authorisation and reimbursement evaluations, and the likeli-
hood of acceptance (and order) for various types of innovative drugs across European 
countries. In the present study, the decision-making process was evaluated, from 
EMA approval to reimbursement decisions, in 4 European countries (UK, Scotland, 
Germany, and France) for innovative drugs (oncology, biological, and orphan drugs). 
Time-to-decision between EMA approval, HTA dossier submission, and reimburse-
ment recommendation were analysed and compared. Subsequently, we assessed 
the order of acceptance (i.e., positive decision) across countries and the likelihood 
of a positive reimbursement decision by drug type after EMA approval. Methods: 
All innovative drugs approved by EMA between 2010 and 2016 were selected. A 
database was created containing the dates of EMA approval, HTA dossier submission 
and reimbursement decisions by the HTA agencies and the actual decision (yes/
no). Median time-to-decision was calculated per innovative drug/country. Decision 
dates, order of approval, and the likelihood for a positive recommendation were ana-
lysed and compared at certain time frames using Kaplan-Meier curves. Results: 
In total, 85 drug evaluations were included (52% oncology, 27% biological, and 21% 
orphan drugs). Median time from market approval until reimbursement decision 
was 14.5 months. Time to reimbursement decision for orphan drugs was shorter 
(12.8 months) compared to oncology (14.8 months), and biological drugs (15.3 
months). The French agency pioneered reimbursement decisions in 46% of the 
cases, followed by Scotland (34%; all corrected by number of decisions per coun-
try). ConClusions: These results indicate that orphan drugs may receive a reim-
bursement approval earlier than oncology or biological drugs. The French agency 
seem to take a leading role in reimbursement decisions. Factors that influence this 
decision-making process need to be further studied to enhance the understanding 
of reimbursement trends in innovative products across countries.
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MEDICAL DEvICE & DIAgNoSTIC RESEARCH STUDIES
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MEDICAL DEvICES: TIMELy ACCESS AND REIMBURSEMENT - CAN NATIoNAL 
HEALTH TECHNoLogy ASSESSMENT BoDIES BE PART of THE SoLUTIoN?
Macaulay R, Shaw S
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objeCtives: Medical devices are typically reimbursed distinctly to pharmaceuticals 
due to their relatively greater number, lower cost, shorter life-cycles, and greater dif-
ficulties in conducting randomized trials. Most new devices are reimbursed under 
existing Diagnosis-related Group (DRG) codes but for new higher-cost innovations, 
reimbursement may be insufficient. Various discretionary funding mechanisms can 
temporarily reimburse a new device until/if a new DRG code is developed. Prices of 
medical devices are typically negotiated between hospitals and companies. Such 
processes can result in significant geographical variation and delays in access. In 
2010, the National Institute for Health and Care Excellence (NICE) set up a program 
(Medical Technologies Evaluation Program [MTEP]) for the appraisal of new/inno-
vative medical devices with claimed patient benefits. This research analyses all 
MTEP guidance and discusses the optimal role of national payers in device reim-
bursement. Methods: All publically-available NICE MTEP guidance was screened 
and key information extracted to 17/06/2016. Results: 29 appraisals were identi-
fied (annual average: 5.4: 2016 (2), 2015 (5), 2014 (6), 2013 (5), 2012 (3), 2011 (7), 2010 
(1)) including cardiovascular (9), general surgery (6), dermatology (4), urology (3), 
